Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.
Chemically synthesized short DNA sequences are extremely important ingredients with countless uses in research laboratories, hospitals, and in industry, like in the method for identifying COVID-19.
Human cells typically transcribe half of their roughly 20,000 genes into RNA molecules at any given time. Just like with proteins, the function of those RNA species not only relies on their abundance but also their precise localization within the 3D space of each cell.
Antibodies are remarkable biomarkers: they are the cues that provide us with indications about many diseases and how our immune system counter them. Now a group of scientists from the University of Rome, Tor Vergata (Italy) has found a way to repurpose them so that they can trigger a specific chemical reaction.
Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.
Bioengineers have demonstrated that RNA produced by the human genome is found on the surface of human cells.
Short RNA molecules can be used as medication. Their effectiveness is based on the genetic information they carry: therapeutic RNA can bind to the body's own RNA and thus influence how it functions.
The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.